Lv5
1140 积分 2022-04-13 加入
OWL833, an Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys
2天前
求助中
Development of a Manufacturing Process for a Key (S)-5-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1H-indole Intermediate for Orforglipron. Part I. Selection of an Evans Auxiliary-Assisted Asymmetric 1,4-Addition Route
5天前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
5天前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
5天前
已完结
336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
5天前
已关闭
Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study
5天前
已完结
Exploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R
5天前
已完结
Abstract 6388: Exploiting CTPS1 dependency for the treatment of breast and ovarian cancer
27天前
已关闭
STP938, a Novel, Potent and Selective Inhibitor of CTP Synthase 1 (CTPS1) Is a Targeted Therapy Specifically Blocking De Novo Nucleotide Synthesis in Lymphomas and Leukemias
27天前
已完结
Structural basis for isoform-specific inhibition of human CTPS1
27天前
已完结
皖公网安备34019202002308
